Version 1.3, revision planned in 2013.
Last revised in February 2009
February 2011 — updated. The new recommendations from NICE technology appraisal 210 Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events have been incorporated into this topic [NICE, 2010]. Issued in February 2011.
July 2010 — minor update. Text added to include NICE Quality Standards relating to Stroke in the NICE Quality Standard section [NICE, 2010]. Issued in August 2010.
July 2009 — minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued advice on the interaction between clopidogrel and proton pump inhibitors. Healthcare professionals are advised to avoid concomitant use of these drugs unless considered essential [MHRA, 2009]. Issued in July 2009.
April 2009 — updated to include the indicators related to stroke and transient ischaemic attack in the Quality and Outcomes Framework (QOF) of the General Medical Services (GMS) contract in the Goals and outcome measures section. Issued in May 2009.
September 2008 to February 2009 — converted from PRODIGY guidance to CKS topic structure. The evidence-base on primary care treatments has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.
The title has been changed from TIA — not in atrial fibrillation to Stroke and TIA, to reflect a wider scope, which now includes the primary care management of stroke. Changes to the sections on transient ischaemic attack (TIA) reflect new guidance from the National Institute for Health and Clinical Excellence (NICE) on using the FAST screening tool when diagnosing TIA, and on standards for referral for specialist assessment.